Novo Nordisk CEO Lars Fruergaard Jrgensen said this March that the gap between demand for weight loss drugs and the supply is significant enough to take years to close
Specifically, for this retrospective cohort analysis, ~200,000 patients from 90 HCOs were identified
Mazza, E., Troiano, E., Ferro, Y., et al
About 1.7% of people in the US have been prescribed a semaglutide medication in 2023, up 40-fold over the past five years, according to data shared exclusively with CNN by Epic Research that was based on an analysis of millions of electronic health records
They found patients prescribed semaglutide (a glucagon-like peptide receptor, or GLP-1R) had a significantly lower risk for Alzheimers disease, compared to those who had taken any of seven other anti-diabetic medications, including other types of GLP-1R-targeting medications